Overview

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

Status:
Recruiting

Trial end date:
2026-04-15

Target enrollment:

Participant gender:

Summary

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo). Participants will be in the study for up to 56 weeks.

Phase:

Phase 3

Details

Lead Sponsor:

Takeda

Treatments:

Apremilast